229 related articles for article (PubMed ID: 15913990)
1. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
4. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann JS; Baker L
Clin Cancer Res; 2002 Mar; 8(3):788-93. PubMed ID: 11895910
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
[TBL] [Abstract][Full Text] [Related]
10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.
Anninga JK; van de Vijver MJ; Cleton-Jansen AM; Kristel PM; Taminiau AH; Nooij M; Egeler RM; Hogendoorn PC
Eur J Cancer; 2004 May; 40(7):963-70. PubMed ID: 15093570
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma.
Ye D; Maitra A; Timmons CF; Leavey PJ; Ashfaq R; Ilaria RL
J Pediatr Hematol Oncol; 2003 Jun; 25(6):459-66. PubMed ID: 12794524
[TBL] [Abstract][Full Text] [Related]
13. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
14. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.
Somers GR; Ho M; Zielenska M; Squire JA; Thorner PS
Pediatr Dev Pathol; 2005; 8(5):525-32. PubMed ID: 16211448
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
16. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
[TBL] [Abstract][Full Text] [Related]
17. Cell surface receptor expression patterns in osteosarcoma.
Hassan SE; Bekarev M; Kim MY; Lin J; Piperdi S; Gorlick R; Geller DS
Cancer; 2012 Feb; 118(3):740-9. PubMed ID: 21751203
[TBL] [Abstract][Full Text] [Related]
18. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
[TBL] [Abstract][Full Text] [Related]
20. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
